Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine)

Veterinary and Comparative Oncology

Volumn 7, Issue 4, 2009, Pages 244-255

  Hosoya, K ^a   Lord, L K ^a   Lara Garcia, A ^a   Kisseberth, W C ^a,b   London, C A ^a,b   Couto, C G ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Dog; Hepatotoxicity; Lomustine; Tumour

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; LOMUSTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; MALE; METABOLISM; RETROSPECTIVE STUDY; RISK FACTOR; TOXIC HEPATITIS;

ALANINE TRANSAMINASE; ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FEMALE; LOMUSTINE; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

CANIS FAMILIARIS;

EID: 70450064740     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2009.00197.x     Document Type: Article

References (29)

1. Saba CF, Thamm DH, Vail DM. Combination chemotherapy with l-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. Journal of Veterinary Internal Medicine 2007, 21:127-132.
2. Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Lisa Barber L, Kent MS, LeBlanc AK, Sabhlok A, Mauldin EA, Shofer FS, Couto CG, Sørenmo KU. CCNU for the treatment of dogs with histiocytic sarcoma. Journal of Veterinary Internal Medicine 2007, 21:121-126.
3. Risbon RE, de Lorimier LP, Skorupski KA, Burgess KE, Bergman PJ, Carreras J, Hahn K, LeBlanc A, Turek M, Impellizeri J, Fred R, Wojcieszyn JW, Drobatz K, Clifford CA. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004). Journal of Veterinary Internal Medicine 2006, 20:1389-1397.
4. Williams LE, Rassnick KM, Power HT, Lana SE, Morrison-Collister KE, Hansen K, Johnson JL. CCNU in the treatment of canine epitheliotropic lymphoma. Journal of Veterinary Internal Medicine 2006, 20:136-143.
5. Rassnick KM, Moore AS, Williams LE, London CA, Kintzer PP, Engler SJ, Cotter SM. Treatment of canine mast cell tumors with CCNU (lomustine). Journal of Veterinary Internal Medicine 1999, 13:601-605.
6. Moore AS, London CA, Wood CA, Williams LE, Cotter SM, L'Heureux DA, Frimberger AE. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. Journal of Veterinary Internal Medicine 1999, 13:395-398.
7. Fulton LM, Steinberg HS. Preliminary study of lomustine in the treatment of intracranial masses in dogs following localization by imaging techniques. Seminars in Veterinary Medicine & Surgery (Small Animal) 1990, 5:241-245.
8. Sauerbrey ML, Mullins MN, Bannink EO, Van Dorp TER, Kaneene JB, Obradovich JE. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). Journal of the American Veterinary Medical Association 2007, 230:1866-1869.
9. Hoogstraten B, Gottlieb JA, Caoili E, Tucker WG, Talley RW, Haut A. CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study. Cancer 1973, 32:38-43.
10. Carter SK, Newman JW. Nitrosoureas: 1,3-bis(2-chloroethyl)-1-nitrosoure (NSC-409962; BCNU) and 1-(2-chloroethyl)-3-chyclohexyl-1- nitrosourea (NSC-79037; CCNU)-clinical brochure. Cancer Chemotherapy Reports 1968, 1:115-151. [3]
11. Kristal O, Rassnick KM, Gliatto JM, Northrup NC, Chretin JD, Morrison-Collister K, Cotter SM, Moore AS. Hapatotoxicity associated with CCNU (lomustine) in dogs. Journal of Veterinary Internal Medicine 2004, 18:75-80.
12. Schaeppi U, Fleischman RW, Phelan RS, Ethier FM, Luthra YK. CCNU (NSC-79037): preclinical toxicologic evaluation of a single intravenous infusion in dogs and monkeys. Cancer Chemotherapy Reports 1974, 5:53-64.
13. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004, 2:195-213. Veterinary Co-operative Oncology Group (VCOG)
14. Center SA. Interpretation of liver enzymes. Veterinary Clinics of North America: Small Animal Practice 2007, 37:297-333.
15. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data 2003, 243-328. 2nd edn., New York, Springer
16. Cleves MA, Gould WW, Gutierrez RG. An Introduction to Survival Analysis Using Stata 2004, 175-190. revised edn, College Station, TX, Stata Press
17. Henry MC, Schein PS. Hepatotoxicity of 1-(2-chloroethyl)-3-chyclohexyl-1-nitrosourea (CCNU) in dogs: the use of serial percutaneous liver biopsies. Toxicology and Applied Pharmacology 1973, 25:410-417.
18. Bain PJ, Latimer KS, Mahaffey EA, Prasse KW. Liver. Duncan and Prasse's Veterinary Laboratory Medicine: Clinical Pathology 2003, 193-214. In:, 4th edn., eds.,, Ames, Iowa State Press
19. Potter DW, Reed DJ. Denitrosation of carcinostatic nitrosoureas by purified NADPH cytochrome P-450 reductase and rat liver microsomes to yield nitric oxide under anaerobic conditions. Archives of Biochemistry and Biophysics 1982, 216:158-169.
20. Weber GF, Waxman DJ. Denitrosation of the anti-cancer drug 1,3-bis(2-chloroethyl)-1- nitrosourea catalyzed by microsomal glutathione S-transferase and cytochrome P450 monooxygenases. Archives of Biochemistry and Biophysics 1993, 307:369-378.
21. Smith MT, Evans CG, Soane-Setzer P, Castro VM, Tahir MK, Mannervik B. Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class Mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Research 1989, 49:2621-2625.
22. Waxman DJ. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy-a review. Cancer Research 1990, 50:6449-6454.
23. Jang I, Jung K, Cho J. Age-related changes in antioxidant enzyme activities in the small intestine and liver from Wistar rats. Experimental Animals 1998, 47:247-252.
24. Fujita S, Kitagawa H, Ishizawa H, Suzuki T, Kitani K. Age-associated alterations in hepatic glutathione S-transferase activities. Biochemical Pharmacology 1985, 34:3891-3894.
25. Rao G, Xia E, Richardson A. Effect of age on the expression of antioxidant enzymes in male F344 rats. Mechanism of Ageing and Development 1990, 53:49-60.
26. Lubet RA, Dragnev KH, Chauhan DP, Nims RW, Diwan BA, Ward JM, Jones CR, Rice JM, Miller MS. A pleiotropic response to phenobarbital-type enzyme inducers in the F344/NCr rat: effects of chemicals of varied structure. Biochemical Pharmacology 1992, 43:1067-1078.
27. Parkinson A, Safe SH, Robertson LW, Thomas PE, Ryan DE, Reik LM, Levin W. Immunochemical quantitation of cytochrome P-450 isozymes and epoxide hydrolase in liver microsomes from polychlorinated or polybrominated biphenyl-treated rats: a study of structure-activity relationships. Journal of Biological Chemistry 1983, 258:5967-5976.
28. Ritter JK, Franklin MR. High magnitude hepatic cytochrome P-450 induction by an N-substituted imidazole antimycotic, clotrimazole. Biochemical Pharmacology 1987, 36:2783-2788.
29. Ahmed AE, Grissom M, el-Azhary R, Haque A, Boor PJ, Costanzi J. Studies on the mechanism of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)-induced hepatotoxicity. II. Biochemical and morphological characterization of the injury and its prevention by phenobarbital. Cancer Chemotherapy and Pharmacology 1987, 19:103-108.